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Understanding how transplant data are collected is
crucial to understanding how the data can be used. The
collection and use of Organ Procurement and Trans-
plantation Network/Scientific Registry of Transplant
Recipients (OPTN/SRTR) data continues to evolve,
leading to improvements in data quality, timeliness
and scope while reducing the data collection burden.
Additional ascertainment of outcomes completes and
validates existing data, although caveats remain for
researchers. We also consider analytical issues related
to cohort choice, timing of data submission, and trans-
plant center variations in follow-up data. All of these
points should be carefully considered when choosing
cohorts and data sources for analysis.
The second part of the article describes some of the
statistical methods for outcome analysis employed by
the SRTR. Issues of cohort and follow-up period se-
lection lead into a discussion of outcome definitions,
event ascertainment, censoring and covariate adjust-
ment. We describe methods for computing unadjusted
mortality rates and survival probabilities, and estimat-
ing covariate effects through regression modeling. The
article concludes with a description of simulated allo-
cation modeling, developed by the SRTR for compar-
ing outcomes of proposed changes to national organ
allocation policies.
Note on sources: The articles in this report are based on the ref-
erence tables in the 2005 OPTN/SRTR Annual Report, which are
not included in this publication. Many relevant data appear in the
figures and tables included here; other tables from the Annual Re-
port that serve as the basis for this article include the following:
Tables 1.5, 5.2, 5.8–5.11, 6.2, 6.8–6.11, 7.2, 7.8–7.11, 8.2, 8.8–
8.11, 9.8–9.11, 10.2, 10.8–10.11, 11.8–11.11, 12.2, 12.8–12.11,
13.2 and 13.8–13.11. All of these tables may be found online at
http://www.ustransplant.org.
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Introduction
In articles corresponding with this one in the SRTR Report
on the State of Transplantation of the three previous years,
we have discussed a range of topics, including: the scope
of transplant data available and the evolution of data collec-
tion mechanisms; how that data collection system is im-
proving the quality of these data and reducing the data col-
lection burden; how additional ascertainment of outcomes
both completes and validates existing data; and caveats
that remain for researchers (1–3). This year, in the first sec-
tion of this article we continue to build upon that founda-
tion and focus on two key areas: (i) a brief summary of the
scope of data available; (ii) further discussion on the im-
provements of data submission patterns both on the wait-
ing list and after transplant, as well as their implications for
analysis.
Since this article now combines elements of analytical
methods with the discussion of the database design, there
is a separate, second section which reviews some es-
sential analytical approaches which are frequently used
by the Scientific Registry of Transplant Recipients (SRTR),
including those used in the 2005 OPTN/SRTR Annual
Report, the Center-Specific Reports (CSRs) published at
www.ustransplant.org, and analyses pertaining to data re-
quests from the Organ Procurement and Transplantation
Network (OPTN) committees and the Secretary’s Advisory
Committee on Organ Transplantation (ACOT). The types of
analyses conducted by the SRTR can be broadly classified
as either unadjusted (‘crude’) or covariate-adjusted; the for-
mer are used primarily for descriptive purposes, while the
latter focus on determining the relative importance of var-
ious factors on the outcome or for drawing risk-adjusted
conclusions. Unadjusted and covariate-adjusted analyses
will be discussed separately.
Overview
This article has been reformulated to combine the discus-
sion of the database design with the discussion of cohort
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selection and choosing the appropriate methods for analy-
ses. It includes new information on which transplant recip-
ients become lost to follow-up (LTFU) and how this varies
not only over time but also by the organ transplanted.
It is important that researchers using transplant data have
an understanding of the scope and structure of available
data, and that they be familiar with how these data are col-
lected. Readers seeking more detailed background about
the structure and source of available data should refer
to ‘Transplant Data: Sources, Collection and Caveats’ (2),
which also includes a more detailed discussion of initial
multiple-source validation of mortality data. Readers seek-
ing a more comprehensive description of the UNetsm data
collection system and recent improvements should see
‘Data Sources and Structure’ (1).
Data reported by transplant centers and organ procure-
ment organizations (OPOs) to the OPTN are an increas-
ingly rich source of information about the practice and out-
comes of solid organ transplantation in the United States.
The SRTR has expanded the spectrum of addressable re-
search questions on transplant outcomes, as well as the
accuracy with which they are answered, by linking data
from the OPTN to several other data sources (SSDMF [So-
cial Security Death Master File], CMS [Centers for Medi-
care and Medicaid Services], NDI [National Death Index],
SEER [Surveillance Epidemiology and End Results], and
NCHS [National Center for Health Statistics]), as described
in ‘Transplant Data: Sources, Collection and Caveats’ (2).
New procedures implemented by the SRTR for including
additional ascertainment of outcomes, such as mortality,
may also have implications for transplant centers’ ability
and motivation to report these statistics. Another result of
such linkages is the ability to study in detail outcomes other
than mortality and graft failure. For example, Schaubel and
Cai recently used the linked SRTR and CMS databases to
compare hospitalization rates on the waiting list and after
transplant (4).
Data quality and timeliness continue to improve from 1 year
to the next. OPOs and transplant centers are increasingly
familiar with new, more efficient data collection tools im-
plemented by the OPTN. These factors make it impor-
tant for researchers to continually remain aware of cur-
rent measures of data timeliness in choosing cohorts,
deciding on methods and watching for potential biases
in their analyses. The statistical methods chosen by the
SRTR for any particular analysis depend strongly on the
nature of the research question. SRTR analyses often in-
volve time-to-event data, which are inherently incomplete
since, inevitably, the observation period concludes before
all subjects have experienced the event of interest (e.g.
transplantation, death or graft failure). Each method de-
scribed later in this article requires careful consideration
of the sequence of events for each individual organ and
patient.
Database Design and Data Structure
A researcher seeking to fully understand the database de-
sign and the data structure of the SRTR may want to start
with the ‘units of analysis’. Figure 1 shows a useful method
of organizing transplant data into these ‘units of analysis’.
These units of analysis are designed to be of most use
to researchers asking questions about the events or out-
comes that may follow the placement of a candidate on
the waiting list, organ donation, or a transplant itself. The
data table in Figure 1 relates to specific subjects of inter-
est for research: candidacies, donors, transplants, and the
components thereof. Also shown are some of the more
specialized tables, ones from which researchers might an-
alyze organ turndowns, use of immunosuppression medi-
cations, or changes in waiting list status prior to transplant.
Three tables in Figure 1 are the entry points for individual
persons into the transplant process: the candidate registra-
tion table (which includes registrants who become trans-
plant recipients), and the living and deceased donor ta-
bles. Underlying these three individual level tables (and
not shown in the figure) is a ‘Person Linking Table’ (PLT)
that is vital to the integration of multiple data sources dis-
cussed later. The PLT holds one record per person, estab-
lishes links on the basis of similarities in Social Security
Numbers (SSNs), names and nicknames, dates of birth,
and other person-level information, while accounting for
many of the mistakes that may occur in entering data in
these fields. The maintenance of this identification roster,
with aggregated identification information compiled from
all data sources, facilitates a system of matching to both
external data sources and other records within the OPTN
data, such as for persons who receive multiple transplants
or even for donors who later become recipients.
In addition, this figure documents some of the primary and
secondary data sources that may contribute to each table.
Further detail regarding the specific data collection instru-
ments, before the information is aggregated to records of
interest, is shown in Figure 2.
Waiting list data
In Figure 1, the ‘candidate registration’ table holds records
for potential transplant recipients: patients who are placed
on the waiting list as well as patients who receive living
donor transplants without having been waitlisted. Analyt-
ically, this table helps researchers describe the ‘demand’
side of the transplant process, comparing characteristics of
successful and unsuccessful transplant candidates and de-
scribing disease progression among prospective recipients
while they are not transplanted, although the researcher
must be cautious of the bias introduced by transplanting
some of these patients, as discussed later. These candi-
dates act as a useful comparison to those who do receive
transplants; considering the consequences of not being
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Figure 1: Transplantation research data organization, primary and secondary sources.
transplanted can be helpful in evaluating the benefit of
transplanting each type of patient. Because mortality plays
such an important role in evaluating transplant benefit, the
examination of the timeliness and accuracy of candidate
data sources presented in this section focuses in particu-
lar on the reliability of mortality information.
Primary sources: The primary source of information
about candidates for transplantation is the OPTN database,
which stores information about all persons on the national
waiting lists. Transplant centers must continuously main-
tain their waiting lists by reporting on changes in severity
of illness (for some organs) and other outcomes, such as
transplant or death. Information in this table is taken from
these waiting list maintenance records and the Transplant
Candidate Registration (TCR) record completed soon after
registration.
Because the maintenance of the waiting list is continuous,
researchers should be able to report upon waiting list out-
comes soon after they happen. In actuality, this depends
on the outcome. Removal from the waiting list for trans-
plant is linked to the generation of a transplant record, so
reporting is nearly immediate. Reporting of death on the
waiting list may display more lag in reporting, particularly
among patients who are offered organs less frequently
because of low severity of illness or accumulated wait-
ing time, since turndown of offers often spurs waiting list
maintenance.
Timing of waiting list maintenance: Table 1 helps an
analyst assess the currency of waiting list data for mor-
tality analyses by showing the time between death and
removal from the waiting list for death. The first three
columns show evidence of improved timeliness of wait-
ing list removal for death, though the statistics reported
for 2004 may overstate completeness at any point in time
because not all deaths during 2004 have been reported
yet. About three-quarters of the deaths that are reported
by the centers are reported within 2 months of their occur-
rence. This profile of lag time in reporting can help guide
the researcher in choosing appropriate cohorts for analy-
ses of waiting list outcomes that include mortality, based
on primary data sources.
The reporting of death is less prompt among candidates
for kidney transplant than for other organs: 65% versus
81% for livers and 91% for hearts at 2 months (Table 1).
This difference is expected because of the longer waiting
times and available alternative therapies that may make the
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Source: SRTR and OPTN.
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Figure 2: Data submission and data flow, primary and secondary sources.
Table 1: Lag time to report of death on the waiting list; all deaths of waiting list registrants reported
by center (cumulative percent reported)
All organs, by year of death By organ, year of death = 2003
Time until reporting: 2002 2003 2004 Kidney Liver Heart
On death date 11.8 11.5 10.6 4.1 19.4 34.6
Within 1 month 64.1 64.0 64.4 52.8 76.5 88.9
2 months 72.8 72.6 73.7 65.0 80.6 91.0
3 months 78.6 78.0 79.8 72.5 83.3 92.7
6 months 86.0 86.5 90.5 84.0 88.0 94.5
12 months 94.4 94.1 93.1 94.6 97.5
Source: SRTR analysis, July 2005. Note: figures for more recent years may overstate completeness
at any time because all deaths (i.e. the full denominator) have not yet been reported.
contact between patient and transplant center less fre-
quent. In 2003, nearly 35% of deaths among heart reg-
istrants were reported on the day of death, compared with
less than 5% of kidney registrant deaths.
Extra ascertainment sources: A transplant center’s re-
porting duties end upon each candidate’s removal from the
waiting list. However, events occurring in the months fol-
lowing removal—such as death or transplant at another
center—are frequently interesting analytical endpoints to
the researcher. Therefore, a candidate file may incorpo-
rate additional mortality sources or waiting list, transplant,
and follow-up information reported by other centers for the
same person.
Many of the same additional sources of outcome ascer-
tainment are used for both waiting list analyses and post-
transplant analyses, particularly for mortality. Using the PLT
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(described above) to match patients, results may be incor-
porated from three other ‘secondary’ sources:
(i) Patient linking between OPTN records allows a re-
searcher to tell that a transplant candidate at one cen-
ter has had a death or transplant reported by a different
center or that a graft has failed, on the basis of a re-
transplant at another center.
(ii) The Social Security Death Master File (SSDMF),
publicly available from the Social Security Administra-
tion (SSA), contains over 70 million records created
from reports of death to the SSA, for beneficiaries and
nonbeneficiaries alike.
(iii) The CMS-ESRD Database provides data primarily
from Medicare records for ESRD patients, and helps
provide evidence of start of dialysis therapy, resump-
tion of posttransplant maintenance dialysis indicating
graft failure, or death.
In addition, the National Death Index (NDI) is available for
validation of the completeness of these sources, though
its use is not permitted for most analyses. The NDI, based
on death certificate information submitted by state vital
statistics agencies, misses only about 5% of all deaths in
the United States.
In 2002, the SRTR and OPTN jointly obtained data from
the NDI for a sample of transplant candidates and patients
to evaluate the completeness of mortality reporting in the
other existing data sources. As the SRTR presented in this
forum in 2002, the majority of deaths are reported by the
main transplant center following the patient (1). It contin-
ues to be important to use all of these available sources in
doing mortality analyses: of patients receiving a transplant
between July 1, 1999 and June 30, 2004 (those included in
the most recent CSR cohort), 78% of kidney and pancreas
transplant recipient deaths were reported by the trans-
planting center. It is still the case that significant fractions
of all the deaths are reported by other available sources,
as 19% of these deaths were reported by the SSDMF and
3% of the deaths were reported first by another transplan-
tation program. In cases where discrepancies arise among
different death dates reported, the SRTR most often relies
on what is reported by the center, first and foremost. The
primary reason for this decision is that deaths are often
reported to the SSDMF as occurring on either the first or
last day of the month, or on the 15th of the month as an
‘average’.
In 2003, the SRTR began using extra ascertainment from
CMS-ESRD data for kidney graft failure for many types of
analyses. A study was conducted to explore the possibility
of supplementing existing SRTR data with CMS graft failure
data for kidney recipients followed by the OPTN. The CMS
data may provide additional information on recipients that
are LTFU, because CMS can be notified about a graft failure
event through several possible mechanisms, in addition to
the OPTN. Further discussion of this work can be found in
‘Transplant Data: Sources, Collection and Caveats’ (2).
Transplant and posttransplant data
The transplants table shown in Figure 1 provides a col-
lected source of information about each transplant event,
including information about the donor, recipient, operation
and follow-up information, summarized to facilitate easy
analyses. This file is used by analysts to describe trends in
the characteristics of transplant recipients, examine trans-
plant outcomes and provide an estimate of posttransplant
survival for comparison to waiting list survival in allocation
policy decisions.
Primary sources: The data for the transplant table are
primarily taken from the Transplant Recipient Registration
(TRR) form collected by the OPTN. Additional characteris-
tics, from the donor and candidate files, are added for ease
of analysis, as are aspects of the interaction between donor
and recipient characteristics (e.g. calculated HLA mismatch
scores; ABO blood type compatibility; whether the organ
was shared, based on the relationship between the OPO
recovering the organ and the transplanting center).
The transplant follow-up data, collected primarily from the
Transplant Recipient Follow-Up (TRF) record, may be sum-
marized to the transplant level, creating indicators of death,
graft failure, and time to follow-up. The expected—and
actual—timing of the follow-up forms are very important
to cohort choice in analyses. After each transplant, follow-
up forms are collected at the 6-month (for nonthoracic or-
gans) and yearly anniversaries (for thoracic and nonthoracic
organs) of the transplant; these forms may also be submit-
ted off-schedule to report such adverse events as graft
failure or death. While transplant follow-ups may be useful
on their own—or in conjunction with their own sub-tables
for immunosuppression or malignancies—for analysis of
specific events that occur during follow-up, they are most
widely used in the summarized form for death and graft fail-
ure analyses discussed here. For such analyses, the timing
is particularly important.
Timeliness of follow-up forms: Just as with events on
the waiting list, it is important to consider the time lag un-
til follow-up forms are filed when determining cohorts for
analysis of posttransplant events. Implementation of new
data collection mechanisms and stricter rules has short-
ened the time until validation. Table 2 shows that the time
from the date of record generation until validation (when
the form has been submitted and verified by the center)
has grown shorter, but it is still nearly 4 months after
each anniversary until four of five forms are submitted, and
6 months before nine of ten are completed. However, the
increase from 91% in 2003 to 97% in 2004 indicates that
the timeliness of submission of routine follow-up forms
continues to improve. If the trend continues, it is likely that
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Table 2: Timing for validation1 of follow-up forms
Cumulative percent validated1 by month
Routine follow-ups Interim follow-ups
Year added 2002 2003 2004 2002 2003 2004
1 Month 26.0 30.6 32.7 43.9 52.8 56.0
2 Months 51.7 60.3 67.3 60.2 70.6 76.1
3 Months 68.3 72.0 80.7 72.2 78.4 84.3
4 Months 77.1 79.3 87.7 79.4 83.7 89.5
5 Months 82.2 86.4 93.3 83.6 88.3 93.5
6 Months 85.9 90.8 97.0 86.5 91.6 96.5
7 Months 89.0 93.8 89.0 93.7
8 Months 91.6 95.8 90.9 95.4
9 Months 93.5 97.1 92.4 96.6
10 Months 94.9 98.0 93.5 97.7
11 Months 95.8 98.7 94.5 98.5
12 Months 96.5 99.3 95.3 99.0
All unvalidated 14.1 9.2 3.0 13.5 8.5 3.5
by 6 months
All unvalidated 3.5 0.7 N/A 4.7 1.0 N/A
by 1 year
Source: SRTR analysis, July 2005.
1The form has been submitted and verified as complete by the
center.
more recent data could be used in analyses in the near fu-
ture. However, a balance must be struck between the need
for recent data and the need for complete data. Currently,
the SRTR typically allows for between 3 and 6 months of
lag time, depending on the need for analyzing data from
the most recent cohort available.
Timing of follow-up forms: In addition to the lag time
until validation of follow-up forms after transplant, the pat-
tern of form submission—often clustered soon after trans-
plant anniversaries—has important implications for avoid-
ing biases when analyzing recent data.
‘Routine’ follow-up forms are generated at each trans-
plant anniversary, yet deaths occur on a continuous ba-
sis throughout the posttransplant period. When a patient
dies during follow-up, the transplant center may file an ‘in-
terim’ follow-up form off the regular reporting schedule for
that patient. This means that centers might report mortality
more quickly and continuously than they report on surviv-
ing patients, for whom they must wait until the transplant
anniversary.
For example, in an analysis of patients transplanted 18
months ago, patients currently alive will have a 1-year
follow-up form indicating their survival until the 1-year
point, with no information beyond that. Patients who have
died, on the other hand, might have follow-up forms in-
dicating death both during the first year and any interim
follow-up forms filed between months 12 and 18. There-
fore, all of the data reported during months 12 to 18 would
be about patients who had died. If a researcher used the
Kaplan-Meier method to take advantage of the most recent
data available, and censored at last follow-up, the portion
of the survival curve calculated after the first year would be
based inappropriately on over-reporting about patients who
had died, thereby creating a bias in mortality reporting. This
bias can be removed by waiting until the living patients are
reported on at the 2-year anniversary. Similarly, 1-month
survival rates cannot be reliably calculated until at least 6
months after transplant (1 year for thoracic organs), after
the anniversaries have prompted reporting on all patients.
The examples given above are extreme cases. However,
including these patients in a sample used for survival calcu-
lations, without appropriate censoring at transplant anniver-
saries, introduces the same bias into the average results.
Further, these caveats are not limited to survival analyses:
other analyses might over-represent outcomes associated
with death in the final 6-month period.
The above example describes the case when transplant
centers may report deaths as they occur. If this were a
reliable pattern of reporting, one analytical solution might
be to assume that the patient is alive unless we know
otherwise. This approach would be effective if the multiple
sources of mortality reliably captured all deaths. However,
all sources are not reliably complete during many periods,
since many deaths are reported as they occur and many
more are reported at the next reporting anniversary, as the
following figures exhibit. Figure 3 depicts when transplant
follow-up forms are filed, comparing those filed for patients
who have died to those for patients who have not. The
actual time of the follow-up event (death in the top panel or
reported as alive in the lower panel) is shown on the y-axis,
and the time that the follow-up form was validated by the
center is shown on the x-axis. If all events were reported as
they occurred, points would fall only along the 45-degree
diagonal dashed line. The horizontal distance, left to right,
between this diagonal and each point represents the time
lag between the event and notification to the OPTN.
The top panel shows this relationship for follow-up forms
reporting deaths, and the pattern of reporting along the
diagonal shows deaths that were reported near the time
of death itself. (In the earlier example of using a cohort
of transplants from 18 months ago to calculate a survival
curve, it is this pattern of reporting along the diagonal for
dead patients that introduces a possible bias beyond the
12-month follow-up time.) There is a more obvious cluster-
ing to the right of each vertical line at 6, 12 and 24 months
after transplant, showing deaths are most often reported
with the timing of routine follow-up forms. The actual death
dates are distributed vertically along the line, emphasizing
the extent to which many centers wait until prompted by
the reporting cycle to report mortality, no matter when the
death actually occurred.
The lower panel of the figure shows a similar clustering
after each reporting anniversary, but the vertical height of
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Figure 3: Time to validation of
death and survivor records.
these clusters, close to the diagonal itself, indicates that
the events being reported on—that the patient is alive—
occurred more recently compared to the reporting date.
This difference is also borne out in the median lag reporting
times, shown by arrows of different sizes in the two panels,
at 133 days for deceased patients and only 28 days for living
patients.
Which recipients are LTFU?: Transplant centers may
have difficulties following transplant patients over time
for a variety of reasons. For example, patients may move
away or transfer their care to other medical profession-
als, or centers may just have a difficult time allocating
staff to report on all patients. There are two different
ways in which patients may become LTFU: (i) the trans-
plant center reports them as being lost, or (ii) the cen-
ter just does not complete follow-up forms for a pa-
tient. About 13% of recipients transplanted with kid-
neys, livers, hearts or lungs since 1997 were LTFU by
the end of the third year after transplant; about three-
quarters of these had been coded as LTFU by the trans-
plant center, and the other quarter had no records com-
pleted for at least the last 1.5 years before the 3-year
anniversary.
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Figure 4: Percentages of
patients lost to follow-up
among centers perform-
ing at least 10 transplants,
1997–2002.
Figure 4 demonstrates that LTFU varies both by the time
since the transplant occurred and by organ. The top panel
shows that not only does the number of patients being
lost increase over time but also that the variation among
transplant centers grows wider. Centers performing fewer
than 10 transplants are not included here as their follow-
up percentage is often quite uneven, depending on the
small set of patients included. Almost all centers were able
to follow at least 89% of their patients in the first year
following a transplant, but after the fifth year half of the
transplant programs had lost more than 14% of patients
to follow-up and 5% of centers had lost over half of their
patients; furthermore, a quarter of the facilities had lost
more than 25% of their patients to follow-up by the fifth
year, although it should be noted that this analysis only
includes transplants from the first half of the period (1997–
1999) due to the lack of sufficient follow-up time for later
transplants.
The bottom panel of Figure 4 shows that LTFU also varies
widely by organ type. Three years after transplantation,
most kidney programs could no longer follow more than
10% of their patients, whereas heart, liver and lung pro-
grams had all lost less than 5% of their patients. Ad-
ditionally, some kidney centers had lost track of more
than one-third of their patients in 3 years, and programs
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transplanting other organ types tended to lose less than
one-fifth of their patients. This is further evidence of the
importance of secondary follow-up data sources, such as
the SSDMF, especially among kidney recipients. The SRTR
continually reviews its data needs for research to assure
that the data items being collected are as complete and
timely as possible. In addition, the Data Working Group
initiated a review of the data elements and frequency of
reporting for long-term follow-up of transplant recipients.
Lag time and cohort selection: For patient survival anal-
yses, the SRTR often adopts a technique of assuming a pa-
tient is alive unless known otherwise, allowing us to follow
patients after they become LTFU. Patients are more prone
to becoming LTFU after receiving a transplant than they
are while still on the waiting list. In prior years, we have
outlined arguments suggesting that even with significant
LTFU, extra ascertainment of mortality makes it plausible
to assume that all sources taken together provide reason-
ably complete ascertainment of death, such that less than
1% of deaths are missed (1).
It is important to continue to choose cohorts carefully, be-
cause the assumption of ‘alive unless we know otherwise’
holds true only during periods when we expect all sources
to be complete and unbiased. This means that a patient
can only be assumed to be alive for the periods in which
follow-data have been reported; it should not be assumed
that the patient will be alive at any point in the future. For
example, if follow-up has been reported at the 2-year an-
niversary of the transplant and there is no indication of
death, it should only be assumed that the patient has sur-
vived for 2 years and not for any period after the data of the
reported follow-up. Additionally, because of the lag time in
reporting, follow-up reporting may not be complete until
2–4 months after the anniversary. As a result, if a cohort
of January 1999 to December 2001 is chosen for analysis,
2-year follow-up would not be complete for the entire co-
hort until approximately March 2004.
Two additional considerations also stand out as being par-
ticularly important in cohort selection. First, a large enough
cohort is desirable to ensure that the corresponding anal-
ysis will have sufficient statistical power. Second, the se-
lected cohort must also reflect the specific aims of the in-
vestigators. These can be somewhat conflicting goals, with
the first enticing one to choose a cohort that spans many
years, but the second often suggesting that only recent ex-
perience be employed. A cohort’s maximum follow-up (e.g.
1-year posttransplant, vs. 5 years) and length (e.g. trans-
plants occurring in 2003, vs. 1999–2003) are inherently con-
nected. For example, if a cohort’s maximum follow-up is
2 years, then survival probability can be estimated only up
to the 2-year point. In the context of posttransplant mor-
tality, to estimate 5-year survival, the cohort must contain
at least some patients who had at least 5 years of poten-
tial follow-up; i.e. were transplanted at least 5 years before
the end of the observation period. Longer follow-up times
necessarily arise from patient experiences that are further
in the past. Since investigators often want to predict the
future prognosis of current patients, and because improve-
ments in medical practices and changes in organ allocation
policy occur rapidly, it is desirable to use the most recent
data available that are relevant to the research question.
In cases where less-recent cohorts are included in mak-
ing predictions for short-term outcome studies, one must
carefully consider the trade-off between improving the pre-
cision and retaining the relevance of an analysis.
The discussion of Figure 3 and the timing of follow-up form
submissions are instructive for choosing a cohort for post-
transplant survival analysis. It is important to choose a com-
bination of survival endpoint (horizontal line) and lag time
(vertical line) that allows for a reasonable capture of both
deaths and survivors. The survival endpoint (12 months)
and additional lag time (+4 months) used for the SRTR
CSRs 1-year posttransplant survival estimate are shown
on the graph. Events in the boxed area are captured from
center reporting, and would also be available in nonmor-
tality analyses such as graft survival. Some events to the
right of the boxed area will be reported by the center, if the
transplant occurred early enough in the cohort to afford
more than 4 months of lag time; others will rely on extra
ascertainment, since center-reporting occurs after the lag
time’s duration.
Having described the SRTR database in the first section,
the article now explains many of the analytic methods em-
ployed to analyze the SRTR data.
Analytical Methods
The second section of this article begins with a description
of the analysis of waiting time until transplant, focusing on
kidney and liver transplantation. A discussion of the anal-
ysis of posttransplant outcomes, including mortality and
graft failure, follows. A general discussion of covariate-
adjusted analysis, followed by a few comments on the lim-
itations of regression models, is next. The final subsection
describes the Simulation Allocation Models (SAMs) devel-
oped by the SRTR to address questions dealing directly
with organ allocation policy.
Analysis of transplant waiting times
Increasing shortages of donor organs relative to the num-
ber of registrants awaiting transplantation holds for each
type of organ failure, with the gap between demand
and supply widening each year. The important issues
in the analysis of waiting time until transplant, focusing
specifically on kidney and liver transplantation, are now
discussed.
Kidney transplantation: For kidney transplants, which
are still allocated primarily according to waiting time and
human leukocyte antigen (HLA) mismatch, the SRTR
1236 American Journal of Transplantation 2006; 6 (Part 2): 1228–1242
Transplant Research Methods, 2005
computes several measures of waiting time. For example,
in the CSRs, key questions addressed include:
1. Among all registrants, what percentage received a
transplant (or other outcome) within a particular time
period (e.g. 6, 12 or 18 months)?
2. By what time after listing had 50% of registrants re-
ceived a transplant?
3. What is the rate of transplantation per time period
among actively listed registrants?
Answers to questions one and two are the most relevant
to waitlisted patients at the time of initial wait-listing, since
each reflects the probability of transplantation while implic-
itly accounting for all potential outcomes (e.g. death prior
to transplantation). Question three is relevant for patients
who are currently active on the waiting list and for evalua-
tion of the allocation process. The first two questions can
be answered directly by evaluating outcomes in different
groups of registrants, while the third involves a measure
of events per unit of patient time (e.g. patient-years).
For the purposes of studying different regions or groups of
registrants, all of the measures described above typically
yield similar conclusions. In addition, an average waiting
time among actual transplant recipients can be easily com-
puted from transplant recipients during a recent interval of
time. This statistic is useful for comparing waiting times
among regions or among transplant programs. However,
the average waiting time among recipients is not useful for
patient counseling, since it does not factor in waiting times
from registered patients who have not received an organ,
or from patients who died or were removed from the wait-
ing list before receiving a donor organ. Although average
time until transplant among recipients has little relevance
to patients currently on the waiting list, the statistic may
be meaningful for the future prognosis of transplant pa-
tients; for example, increased time on dialysis is known
to strongly influence postrenal transplant survival and,
among pediatric patients, the occurrence of developmental
problems.
The outcomes for all wait-listed registrants are summarized
by the fraction who receive a transplant, die without a trans-
plant, are removed from the waiting list for various reasons,
are still surviving after removal from the list, and are still on
the waiting list at various time points after wait-listing. Two
examples of such statistics are described here. Among
all registrants, the fraction transplanted (FT) is reported in
Table 5 of the CSRs at several points in time after list-
ing (30 days, 1 year, 2 years and 3 years) for each trans-
plant program (www.ustransplant.org). The FT is a simple
fraction of all wait-listed registrants who received a trans-
plant, regardless of the program where the transplant was
performed. The FT summarizes the time to transplanta-
tion at any program among all registrants in that transplant
program.
The time to transplant (TT) is the time since listing by which
50% (or another stated fraction) of all wait-listed registrants
receive a transplant. The TT calculation summarizes the
time to transplantation at a transplant program or within a
group, taking into account the possibility of not ever receiv-
ing an organ. The TT measures the rate of transplantation at
a particular program, so registrants who transfer to another
program’s waiting list or who are removed for reasons of
good health are dropped (censored) at that time, using ac-
tuarial methods for the TT outcome. Registrants who die
or are removed from the list for reasons of poor health are
not censored and are counted as never receiving a trans-
plant in both the TT and the FT calculations. Note that the
median TT would never be reached for groups in which
more than 50% of the registrants die or are removed for
poor health, since these registrants are counted as never
receiving a transplant.
Different statistics are useful for the evaluation of organ al-
location policies for deceased donor organs. For example,
rates of transplantation among registrants on the waiting
list are useful for evaluating and comparing the impact of
allocation policies on different groups of registrants. Such
policies only affect registrants while they are active on the
waiting list. The Annual Report shows percentiles of wait-
ing time based on rates of deceased donor transplanta-
tion among all registrants during the time from listing until
removal from the list. For such calculations, time while
inactive is excluded, and registrants are censored at re-
moval from the list for any reason, including death, poor
health, recovery of native organ function, or receiving a liv-
ing donor organ transplant. This measure of waiting time
reflects that, which would result for a hypothetical pop-
ulation with transplant rates identical to those observed,
if all registrants remained active on the waiting list until
transplant.
Liver transplantation: In the setting where organs are
allocated based on waiting list survival probability, the
seemingly simple question, ‘How long do patients wait for
a transplant?’ is no longer so simple to answer. Taking liver
failure as an example, organs are allocated first to patients
with acute liver failure (Status 1), then to chronic liver failure
patients with the highest expected waiting list mortality,
based on the Model for End-stage Liver Disease (MELD)
score that can change over time. Estimation of a patient’s
time until future transplant requires that the probability of
potential future MELD pathways be quantified. Even if the
probability of changing MELD categories is correctly spec-
ified, there is still the issue that changes in MELD are as-
sociated with both changes in waiting list mortality and in
transplant probability itself. In some regions of the country,
registrants with a very low risk of death might never be al-
located an organ unless and until their condition worsens.
Due to the difficulty in projecting waiting time until trans-
plant, other important questions arise when considering
the liver waiting list:
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1. Among registrants with acute liver failure, what fraction
gets a transplant, what fraction dies and what fraction
recovers?
2. Among chronic failure registrants, what is the rate of
transplantation per month during the time that their
MELD score has a particular value? What is the compet-
ing risk that the registrant dies during the same time?
Answering such questions allows for the evaluation and
comparison of access to liver transplantation for both policy
development and registrant counseling. Similarly, for each
organ that is allocated on the basis of medical condition,
it is useful to report the measures of transplantation rates
separately for different categories of medical conditions,
also allowing for and reflecting the possibility of moving
amongst severity levels. Analogous methods can be used
for registrants for other organ transplants, such as heart,
if allocation rules are changed from a waiting-time basis to
include death rates on the waiting list as a criterion.
The use of MELD to allocate livers among chronic liver fail-
ure registrants began in February 2002, along with rules
for exceptions for registrants with other specific diseases,
such as liver cancer (5). The SRTR reports relevant sum-
mary statistics and tables to summarize rates of liver trans-
plantation according to the status and MELD in the CSRs.
The various methods described above are all useful for
describing waiting times for transplantation and each is
appropriate for specific purposes. The choice of method
depends on the specific question or the purpose of the
question.
Unadjusted analysis of patient survival and graft
failure: Unadjusted (crude) methods, such as the ‘actu-
arial method’, use death rates to compute the correspond-
ing conditional survival probabilities for successive time in-
tervals. These interval-specific conditional survival proba-
bilities (i.e. the probability of surviving until the end of the
interval, given that the patient was alive at the beginning of
the interval) are multiplied to yield the cumulative survival
probability for various time points (e.g. 3-year survival). De-
pending on the question posed, these actuarial results are
reported as either the fraction that died, the fraction still
surviving, or the expected years of life through the end of
the last interval.
Unadjusted posttransplant graft and patient survival out-
comes are reported as cumulative ‘success’ rates. These
are calculated by Kaplan-Meier survival curves when the
analyses are based on data from a single cohort, and they
are shown at various time points after transplant. Results
from different cohorts are sometimes shown at various
time points after transplant, as in the Adjusted and Un-
adjusted Graft and Patient Survival tables in the 2005 An-
nual Report. However, since these results are from differ-
ent groups of patients, the results computed across dif-
ferent time periods need not be consistent. For example,
the 5-year survival for the 10-year cohort is not reported
and should not be assumed to be the same as the 5-year
survival that is reported for the 5-year cohort.
Mortality: Generally speaking, wait-listed registrants are
not tracked by their former listing centers for mortality
after removal from the waiting list. That is, mortality as-
certainment stops when a recipient is LTFU. Because of
the incomplete follow-up available in the data, the actuar-
ial methods described above must censor patients when
they are LTFU. If the failure rates after LTFU are the same as
the failure rates among those still being followed, then the
actuarial method estimates are appropriate, even though
some observations were censored. However, if recipients
at high risk for eventual failure are disproportionately LTFU
before they fail, then the estimated failure rates will under-
estimate the overall failure rates. When many subjects are
LTFU, it is important to know if they were at high or low
risk for subsequent unobserved events, compared with pa-
tients under observation.
OPTN death ascertainment, along with extra ascertain-
ment from the SSDMF and the ESRD database, were used
to compute death rates on the waiting list, as reported
in each organ-specific section in the 2005 Annual Report.
Such follow-up stops when a candidate is removed from
the waiting list, because organ allocation is not affected
by events after removal from the waiting list. The death
rate per patient-year at risk method includes events and
time only while on the waiting list and is not affected by
events after removal. However, the resulting death out-
comes are difficult to interpret because registrants are of-
ten removed from the list if their health deteriorates to
the extent that they are no longer suitable for a transplant.
Thus, low death rates on a waiting list are likely to reflect
an effective screening process, which systematically re-
moves (or transplants) patients when their health dete-
riorates. Rates based on patients not removed from the
waiting list do not apply to registrants, in general, but to
patients currently on (i.e. not removed from) the waiting
list.
For the CSRs, mortality rates on the waiting list include ex-
tra ascertainment for death after removal from the waiting
list or, in some cases, before removal. For these analyses,
time at risk begins at the start of the observation period or
the date of first wait-listing (latter thereof) and continues
until the date of death, transplant, 60 days after removal
for recovery, transfer to another center, or the end of the
observation period (earliest thereof).
To compute expected lifetimes on the waiting list, the
SRTR uses information on deaths from other data sources,
such as the SSDMF. This is especially important when
comparing pretransplant mortality (which includes time
after removal from the waiting list) to posttransplant
mortality.
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Graft failure: The analysis of graft failure is complicated
by the potential for recipients to die. Death serves as a
competing risk in the sense that the time of graft failure
cannot be observed among patients who die with a func-
tioning graft (6). Death-censored graft failure estimates the
‘cause-specific’ rate of graft failure; i.e. the rate of graft
failure among patients who have not yet died. This is an
interpretable measure that is frequently used. However,
cause-specific rates, such as those estimated in an analy-
sis of death-censored graft-failure, can only be combined to
produce a meaningful survival curve if the competing risks
are independent, an untenable assumption in the context
of death and graft failure.
Frequently in analyses of graft failure, the end-point is de-
fined as the minimum of the time until death and time
until graft failure. This results in a well-defined lifetime (i.e.
survival, with a functioning graft). If only graft failure were
specifically of interest, one could argue that the graft is, by
definition, truly no longer functioning after the patient dies.
In the regression setting, the trade off for a cleanly-defined
end-point is the interpretation of the covariate effects. For
example, if a patient characteristic significantly increases
the rate of graft failure, but not the rate of death, an analysis
which combines graft failure and death may identify the co-
variate as being nonsignificant. In order to understand the
mechanisms that lead to transplant failure, it is sometimes
useful to count only failures of the transplanted organ itself,
while not counting deaths from other causes. In addition to
the issue of graft failure and death being competing risks,
there is also the issue of determining exactly which events
constitute graft failure. For example, when a graft failure is
not explicitly recorded in the database, but a retransplant
is recorded, the date of retransplantation can be used as
the date of graft failure. In addition, for kidney transplant
recipients, a reported return to dialysis can be counted as
an organ failure.
Covariate-adjusted analyses
Analyses with covariate adjustment, such as regression
modeling, are intended to compare patient subgroups with
‘all other factors being equal’. Many of the analyses per-
formed by the SRTR involve comparisons of outcomes.
For example, for tables comparing adjusted 1-year survival
over 10 years of transplantation, adjustment helps ensure
that differences from year to year are not due to changes in
case mix. Also, the CSRs use covariate adjustment to com-
pare center-specific mortality rates with what would be ex-
pected for a given case mix, allowing the reader to separate
which part of a good result, for example, is due to patient
case mix. The process of covariate risk-adjustment, known
as ‘indirect standardization’, is detailed in ‘SRTR Center-
Specific Reporting Tools: Posttransplant Outcomes’, an ac-
companying article in this report (7).
The SRTR often uses an adjustment method based on re-
gression models, to compare the outcomes that would
have resulted had the comparison groups been otherwise
equivalent. Regression models can be used to compute
expected outcomes given a patient’s characteristics. The
Cox proportional hazards regression model is commonly
used for adjusted analyses of time-to-event data (8). Simi-
lar to the Kaplan-Meier estimates described above, the Cox
regression model can yield the survival curve estimates for
two or more groups of patients, adjusted to show the com-
parison that would result if the groups were equivalent with
regard to particular factors, such as age and diagnosis.
Adjusted analyses are used extensively by the SRTR in the
CSRs and in analyses based on data requests from com-
mittees. The choice of what to adjust for, or what to make
equal in the comparison groups, is an important one that is
under constant review by the SRTR and will differ accord-
ing to the specific purpose of the analysis. For example, in a
comparison involving patient characteristics (e.g. mortality
rates by ethnicity), it would be prudent to adjust for vari-
ables reflecting therapeutic regimen, if available. However,
in an analysis comparing center-specific transplant mortal-
ity rates, therapeutic regimen reflects a center’s practices.
To adjust for such factors amounts to adjusting away the
difference that, if present, one wishes to discern. To make
meaningful adjustments, relevant data must be available,
complete, and accurate. The choice of factors used when
adjusting center-specific outcomes for the mix of charac-
teristics at each center involves OPTN committees and
SRTR analysts. The documentation of CSRs (available at
www.ustransplant.org/programs-report.html) includes de-
tailed descriptions of the adjustment models they use.
Naturally, covariate adjustment is generally limited to pa-
tient characteristics for which data are collected and, with
respect to the SRTR, limited comorbidity data are avail-
able. The extent to which lack of comorbidity data biases
the results of a regression analysis is an open question. For
example, suppose that bodymass index (BMI) is the covari-
ate of interest in a kidney posttransplant model, with car-
diovascular disease (CVD) being the potential confounder.
The BMI regression coefficient, based on a model which
does not contain a CVD covariate, would result in a biased
estimate of the BMI effect only if CVD is both predictive
of mortality and correlated with BMI after adjusting for all
covariates which are included in the model. That CVD is a
mortality risk factor alone would not mean that the BMI co-
efficient is biased if CVD were not included in the model.
Although it is quite possible that CVD is correlated with
BMI, the pair-wise correlation is of no relevance to the issue
of bias; the pertinent correlation is that between BMI and
CVD, adjusting for all other model covariates, which would
be substantially less than the crude pair-wise correlation.
In the assessment of potential residual confounding, it is
often useful to compare the crude and covariate-adjusted
analyses. For example, it would be encouraging if the unad-
justed and covariate-adjusted hazard ratios for BMI were
similar. That is, if there is little difference in the results
which are unadjusted and the results which are adjusted
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for all available covariates, the hypothesis of residual con-
founding would be much less convincing. Nonetheless, the
potential for residual confounding is frequently a consider-
ation in SRTR analyses, mostly because it is impossible to
verify its absence.
Further comments on regression modeling of time-to-
event data: Since its development in the 1970s, the Cox
regression model has become the predominant method of
analyzing survival data (8). The popularity of the Cox regres-
sion model is well founded. The model is semiparametric,
in the sense that covariates are assumed to act multiplica-
tively on the baseline event rate (parametric), but that no
functional form is assumed for that baseline event rate
(nonparametric). The key advantage of the Cox model is
that no specific survival model is assumed; that is, the rela-
tionship between the covariates and mortality is specified,
such that covariate-adjusted mortality between subgroups
can be compared. However, baseline mortality itself is not
specified by the Cox model. In contrast, fully parametric
models are valid only if the model specified truly fits the
data. For example, hazard ratios based on a Weibull model
will be biased if the Weibull model does not actually hold.
Therefore, if covariate effects are of primary interest in a
survival analysis, the Cox model is the method of choice
for the SRTR and for biostatisticians in general. If survival
predictions are of interest, a parametric model is simpler
to apply. However, the predictions will be accurate to the
extent the chosen model holds. Since the baseline hazard
can be estimated nonparametrically under the Cox model,
it still may be preferred even if prediction is the goal, in the
interests of accuracy.
Despite its utility and flexibility, limitations exist with re-
spect to regression models used for survival analysis, in-
cluding the Cox model. For example, residual plots are gen-
erally difficult to interpret and the identification of patterns
is a subjective matter. The more sophisticated methods
recently developed are computationally intensive, to the
point of not being feasible for data sets as large as those
typically analyzed by the SRTR. In addition, global mea-
sures of fit are not available through any standard software
packages and would be time-consuming and computation-
ally demanding. Clearly, further development is needed
with respect to regression diagnostics for survival models.
Should the Cox model be found to provide inadequate fit
to the data, alternative models include the additive hazard
models of Lin and Ying (9) and Aalen (10).
The need for simulation models in addressing organ al-
location issues: Thus far, the survival models discussed
in this article have dealt with a single end-point, be it mor-
tality, graft failure or some other outcome. In such cases, a
single model equation describes the relationship between
patient characteristics and, for example, patient survival.
Questions such as ‘How quickly does the mortality rate in-
crease with increasing age?’ or ‘How much higher is the
death rate for diabetics relative to patients without dia-
betes?’ can be addressed directly through a single regres-
sion model. However, many questions of interest from an
organ allocation perspective are not nearly as straightfor-
ward to address, such as ‘What would be the difference in
the number of deaths per year if a minimum MELD score
was required for liver transplantation?’ No single model
equation could address this question, since it is affected
by many input systems, including organ donation, accep-
tance of offered organs, patient waiting list and posttrans-
plant survival, degree of organ sharing (e.g. regional, na-
tional), and rates of new listings. No single model could
accurately describe the entity of interest and, in fact, sep-
arate models would be required for each of the aforemen-
tioned systems. Therefore, rather than attempt to build a
model of the interplay between these systems, it is eas-
ier to simulate patient experience under various conditions
(e.g. a change in allocation rules). We now describe the
family of simulation models developed by the SRTR pri-
marily to quantify the potential impact of changes in organ
allocation policies.
Simulated Allocation Modeling
The simulated allocation models (SAMs) developed by the
SRTR are designed to simulate organ allocation and resul-
tant patient outcomes in the United States. These models,
whose value has been recognized by several OPTN com-
mittees and by the SRTR Scientific Advisory Committee
(SAC), provide a method to compare relative outcomes un-
der alternative allocation policies prior to implementation of
these policies.
HRSA has developed a checklist of steps in the develop-
ment of analyses in support of allocation policy to ensure
that proposed allocation policies can credibly be expected
to satisfy the requirements of the ‘OPTN; Final Rule’. The
SAMs were developed to satisfy one of the important re-
quirements specified by both the checklist and the OPTN
Final Rule; to test the consequences of proposed allo-
cation policies prior to implementation, using simulation
modeling.
Prior to implementing a proposed allocation policy, the
OPTN develops performance indicators to assess the
achievement of the goals of that policy, e.g. equity and in-
creased access for patients with greater medical urgency.
The SRTR can use the SAMs to evaluate allocation policies
based on any performance indicators based on or linkable
to OPTN data that are developed by the OPTN. Thus far,
the SAMs have been used to evaluate OPTN proposed al-
location policies based on waiting list deaths, total deaths
(overall, by zone and by urgency status), transplant eq-
uity (according to race, blood type, sensitization and age
groups), transplant rates and graft failures.
SAMs incorporate both deterministic and random factors.
If the input data are fixed, then the initial waiting list,
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waiting list arrivals, status changes, organ arrivals and rules
of organ allocation are all deterministic. The match run itself
is determined entirely by the allocation rule specification
selected by the user, the organ offered, and the patients
remaining on the waiting list who are available for that
organ.
After the match run has determined the order in which an
organ will be offered to candidates, the remaining events
are determined randomly through various probability func-
tions. These events include the probability of organ place-
ment with each successive candidate in the match run,
time from transplant to death, relisting events and relist-
ing history. Their probability functions depend on candidate
and organ characteristics. Organ placement is modeled us-
ing logistic regression, with adjustments for relevant candi-
date demographics, clinical factors, organ factors, and fac-
tors based on the particular organ and candidate involved
(e.g. HLA match, distance, etc.). Posttransplant mortality
is predicted using Cox regression models for time from
transplant to death, with adjustments for organ, recipient
and organ/recipient factors. Figure 5 shows the time order
in which events are processed in SAMs (11).
Each of the SAM computer programs handles events in
a time-ordered sequence. Event queues are maintained
for organ arrivals, wait-listed candidate status changes (in-
cluding removal and death events), candidate arrivals to
the waiting list, status changes for relisted candidates and
posttransplant death events. Each organ arrival event trig-
gers the organ allocation engine that orders the waiting list
according to the allocation rules specified. The placement
model is then used to determine the probability of organ
placement with the first candidate. A random number is
compared against that probability, with the result determin-
ing acceptance or rejection of the organ. This is repeated
until either the organ is placed or the list of candidates is ex-
hausted. Once an organ placement is made, the candidate
is removed from the waiting list. The posttransplant en-



























Figure 5: SAM event-sequenced modeling processes events
in time order.
possible relisting prior to death. In the case of relisting, the
posttransplant engine also schedules the time to relisting
and candidate status changes while on the waiting list.
Candidate arrival events place candidates on the waiting
list and initialize the descriptions of the candidates such
as medical status, listing center and ABO type. Wait-listed
candidate status change events change the medical status
of a candidate on the waiting list. Any serial data available
from the OPTN can be updated over time for candidates
on the waiting list. These data may then be used in allo-
cation rules, placement models and/or posttransplant sur-
vival models. In addition, waiting list removal and waiting
list death events are triggered through the status change
event queue.
The entire family of organ-specific simulation models
has been developed by the SRTR with input from the
OPTN committees. These include the liver simulated al-
location model (LSAM), the thoracic simulated allocation
model (TSAM), and the kidney-pancreas simulated alloca-
tion model (KPSAM).
Each of these organ-specific SAMs has separate organ-
specific components for inputs (candidate information,
waiting list histories, and donor organ information), alloca-
tion rule specifications, placement models and posttrans-
plant events. SAMs are designed to compare the differ-
ences in outcomes expected between allocation policies
if they were nationally enacted and all other behavior re-
mained the same. Exact replication of actual outcomes for
a given year is not a specific goal, due to the effects of
physician judgment and local variations in the means of
implementing national allocation policy. However, valida-
tion tests comparing the results of these models with the
actual results of particular calendar years has shown ex-
cellent agreement regarding those outcomes that are most
relevant to the comparison of allocation rules. While certain
proposed allocation systems require specific comparisons,
the SRTR typically compares numbers of transplants, or-
gan discards, and patient deaths when examining sets of
proposed allocation systems against current rules.
SAMs have been used in support of OPTN committees
charged with the development of national allocation poli-
cies to assess the effect of over 70 proposed changes to
allocation policies prior to implementation. For instance,
TSAM was used to evaluate the effect of implementing
the new lung allocation policy, which is based on waiting
list urgency and transplant benefit, compared with the pre-
vious system, which was based on waiting time. TSAM
results indicated that lung patient deaths would decrease
and overall patient life-years would increase under the pro-
posed allocation system. LSAM was useful for evaluating
the effect of a new allocation system that involved region-
ally sharing livers for MELD and PELD scores above 15,
the effect of changing the score calculated for adolescents
aged 12–17 from PELD to MELD, and the effect of requir-
ing regional sharing of all pediatric donor livers to children
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from 0 to 11 years old. LSAM results indicated that by ex-
panding the pool of donor organs available to candidates
with higher MELD scores, these policy changes would re-
duce the number of deaths on the waiting list. KPSAM was
used to test the effects of increasing points for zero HLA
DR mismatches for pediatric recipients of kidneys from
donors less than 35 years old. The KPSAM results indicated
a sharp increase in pediatric transplantation rates under the
proposed allocation system.
SAMs can use either actual historical data (and model pa-
rameters) as inputs or, through the data generator, data files
built by resampling actual data according to user-specified
over- or under-sampling specifications. The generated data
can be used to model the simultaneous effects of a hy-
pothesized behavioral change together with proposed rule
changes. For example, in modeling a rule change that pri-
oritizes a certain group of patients, the generator may be
adjusted to reflect a possible increase in the number of pa-
tients wait-listed in that group; the generator might also be
adjusted to raise the number of expanded criteria donors to
be consistent with anticipated OPO focus in that direction.
In summary, SAMs can be used to analyze allocation ef-
fects in several ways: comparing outcomes with differ-
ent allocation rules; generating realistic numbers of organ
transplants and organ discards from the available pool of
donor organs; approximating geographic distributions, or-
gan type and status at transplant when current allocation
rules are used; and enabling differential placement of or-
gans with varying characteristics and compatibility (e.g.
size and blood type). Results from the SAMs have been
used by several OPTN committees in predicting the likely
effects of changes in allocation rules before considering
such rule changes for national policy.
Conclusion
In previous editions of the SRTR Report on the State of
Transplantation, this article focused on data collection and
organization schemes for transplant data, and offered be-
ginning insights into implications of their timing and com-
pleteness. Additionally, in the past, there has been a sep-
arate article on analytical approaches to using these data.
This year the two articles have been combined with the
first part focusing on caveats related to cohort choice, tim-
ing and timeliness of data submission, and potential biases
in follow-up data and the second part addresses using this
knowledge to apply research methodologies properly and
consistently. The numerous methodologies described here
are applied by the SRTR and are tailored to address specific
questions. Statistical adjustments to make ‘all else equal’
for comparisons of variables of interest usually require clin-
ical input and thoughtful consideration. Confounding and
potential biases must always be evaluated. Simulated allo-
cation modeling is particularly valuable when considering
modifications of national policies.
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